Strategic movements and cost reductions …

• Total income: $ 1.3 million for Q2 2025, compared to $ 1 million for Q2 2024.

• Income guidance: The turnover of the entire year 2025 expects between $ 6 million and $ 8 million.

• Total operating costs and costs: $ 13.4 million for Q2 2025, a decrease of 72% of $ 47.4 million in Q2 2024.

• R&D costs: $ 5.9 million for Q2 2025, a decrease of 82% of $ 32.4 million in Q2 2024.

• SG & A expenditure: $ 7.1 million for Q2 2025, a decrease of 53% of $ 14.9 million in Q2 2024.

• Net loss of continuing operations: $ 13.7 million for Q2 2025, compared to $ 47.1 million for Q2 2024.

• Net loss per share: $ 3.38 for Q2 2025, compared to $ 11.79 for Q2 2024.

• Cash and cash equivalents: $ 23.5 million in the US and $ 142.1 million in total consolidated as of June 30, 2025.

• Cash flow: Positive cash flow of $ 13.7 million on a total consolidated basis for Q2 2025.

• Chinese transaction -consideration: It is expected that around $ 210 million, an increase of $ 50 million compared to the initial guidelines.

• Cash Runway: Extended to 2028 Post-China transaction and loan benefit.

Release date: August 11, 2025

For the entire transcript of the profit, consult the full transcript of the profit call.

• Fibrogen Inc (Nasdaq: FGEN) announced an increase in the expected total consideration of the sale of Fibrogen China to around $ 210 million, an increase of $ 50 million compared to the initial guidelines.

• The company has expanded its cash career to 2028 and offers financial stability for future development initiatives.

• Positive type C meeting with the FDA for Roxadustat, tailored to important elements for a crucial phase 3 study for anemia treatment.

• FG-3246, a potential first-in-class ADC, showed promising early efficacy signals in phase 1 studies for metastatic castration-resistant prostate cancer.

• Fibrogen Inc (Nasdaq: FGEN) reported a significant reduction in operating costs and costs, which made 72% year after year.

• Fibrogen Inc (Nasdaq: FGEN) reported a net loss of continued activities of $ 13.7 million for the second quarter of 2025.

• The total turnover of the company for the second quarter was only $ 1.3 million, which indicates generating a limited income.

• There is uncertainty about the final design and approval of the phase 3 study for Roxadustat, which can influence time lines.

• The company is confronted with potential risks and uncertainties with regard to its future -oriented statements and regulatory strategies.

• Fibrogen Inc (Nasdaq: FGEN) has not yet completed its strategy for collaborating or maintaining Roxadustat as a complete possession that could influence future commercialization.